REVIEW
Add like
Add dislike
Add to saved papers

Areas of uncertainty in the management of human trichinellosis: a clinical perspective.

There is disagreement between authorities on most facets of trichinellosis therapy. The most controversial issues are when to use corticosteroids and which antihelminthic drug should be administered, for how long and at what dose. These issues are particularly important in the treatment of severe, potentially fatal infections. A major reason for the lack of consensus regarding trichinellosis management is that there have been very few prospective, controlled clinical trials of this infection. After a brief review of pertinent epidemiological and clinical features of the disease, selected treatment concerns will be discussed and areas where more information is urgently required will be highlighted.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app